Bruker Announces Quarterly Dividend
Bruker Corporation to Present at Upcoming Investor Conferences
Bruker Announces EpicIFTM, Revolutionary Fluorescence Signal Removal Technology, Transforming CellScape Spatial Proteomics Platform
Bruker Co. (NASDAQ: BRKR) had its price target lowered by analysts at Citigroup Inc. from $80.00 to $75.00. They now have a "buy" rating on the stock.
Bruker Co. (NASDAQ: BRKR) had its price target lowered by analysts at TD Cowen from $72.00 to $70.00. They now have a "hold" rating on the stock.